Century Therapeutics, Inc. Business Acquisition, Pro Forma Net Income (Loss)
Century Therapeutics, Inc. (IPSC) reported Business Acquisition, Pro Forma Net Income (Loss) of $6.59 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-19.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2025-03-19
- Century Therapeutics, Inc. business acquisition, pro forma net income (loss) for the quarter ending 2024-12-31 was $4.17M.
- Century Therapeutics, Inc. business acquisition, pro forma net income (loss) for the quarter ending 2024-09-30 was $791.00K, a 434.46% increase year-over-year.
- Century Therapeutics, Inc. business acquisition, pro forma net income (loss) for the quarter ending 2023-09-30 was $148.00K.
- Century Therapeutics, Inc. business acquisition, pro forma net income (loss) for the quarter ending 2023-06-30 was $99.00K.
- Century Therapeutics, Inc. business acquisition, pro forma net income (loss) for fiscal 2024 was $6.59M.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 3 month | Business Acquisition, Pro Forma Net Income (Loss) 6 month | Business Acquisition, Pro Forma Net Income (Loss) 9 month | Business Acquisition, Pro Forma Net Income (Loss) 12 month |
|---|---|---|---|---|
| 2024-12-31 | $4.17M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $4.96M derived: sum of 2 quarters · filed 2025-03-19 | $6.59M 10-K · filed 2025-03-19 | |
| 2024-09-30 | $791.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $2.42M 10-Q · filed 2024-11-05 | ||
| 2024-06-30 | $1.63M 10-Q · filed 2024-08-08 | |||
| 2023-09-30 | $148.00K 10-Q · filed 2024-11-05 | $247.00K derived: sum of 2 quarters · filed 2024-11-05 | $1.97M 10-Q · filed 2024-11-05 | |
| 2023-06-30 | $99.00K 10-Q · filed 2024-08-08 | $1.82M 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |